PL YT FB
flowers flowers 2 3

Prenatal testing – prenatal testing comparison

The Medfemina Health Centre was the first medical facility in Lower Silesia and Wrocław to introduce the latest generation NIFTY genetic test for Down syndrome, Edwards syndrome and Patau syndrome with 99.9% efficiency. Learn more about the prenatal testing and genetic testing we offer.

Prenatal tests and genetic tests and examinations offered by the Medfemina Health Centre in Wrocław (click on the appropriate test to find out more):

  1. NIFTY genetic test– prenatal screening for foetal DNA based on maternal blood material

NIFTY test based on detection of genetic material of the baby (baby’s DNA) circulating in the mother’s blood, allows detection of genetic anomalies of the foetus: Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13) with a very high detection rate of 99.9%. An additional advantage of the test is that it’s non-invasive – the test consists in collecting the mother’s blood, isolating the child’s blood and analysing it. Taking a blood sample is similar to the standard blood count procedure. In addition, if desired by the parents, the sex of the baby can be determined with a very high probability (greater than 99%) during the NIFTY test.

  1. FMF genetic test– Prenatal screening test consisting of genetic ultrasound and biochemical analysis from the mother’s blood

The FMF test (FMF – Foetal Medicine Foundation, based in London) is based on performing an ultrasound examination, called a genetic ultrasound, during which the width of the so-called NT – the nuchal translucency of the foetus – is measured. Additionally, for the FMF test, maternal blood is collected for biochemical tests (betaHCG and Pappa protein). The probability of Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13) is then determined from the data obtained, with a probability of detection between 85% and 90%. The FMF test is performed between 11 weeks and 13+6 days weeks of pregnancy. The test is non-invasive.

  1. Nuchal translucency(NT) measurement – a prenatal screening test performed in the first trimester during what is called a first trimester genetic ultrasound.

Foetal anomaly detection rate of 64% to 70%. Performed between 11 weeks and 13+6 days weeks of pregnancy. Non-invasive method.

  1. Biochemical testing from maternal blood – prenatal screening based on biochemical analysis performed from maternal blood.

Triple test: testing of AFP protein concentration, β-hCG levels, and estriol E3 concentration performed between 14 and 20 weeks of pregnancy.

Detection of foetal malformations in the first trimester of pregnancy at 60% to 80%. Non-invasive examination.

  1. Amniocentesis – An invasive prenatal diagnostic test. It involves puncturing the amniotic cavity with a needle (often under ultrasound guidance). Amniocentesis can be performed as an early amniocentesis after the 14th week of pregnancy or as a late amniocentesis between 15 and 21 weeks of pregnancy. Amniocentesis is an invasive method with a risk of complications such as damage to the placenta, puncture of the foetal organs, intrauterine infection, rupture of the bladder and spontaneous abortion (miscarriage). The method has a very high detection rate of foetal malformations above 99%.

Other prenatal testing (not offered by our Centre):

  1. Chorionic villus sampling (CVS)– invasive diagnostic prenatal examination performed in the first trimester of pregnancy.

Chorionic villus sampling is performed under ultrasound guidance, and then a DNA test is performed on the basis of the collected material. The test is performed between 10 and 14 weeks of pregnancy. It is an invasive method, with a risk of spontaneous abortion (miscarriage), amniotic fluid leakage, and minor bleeding. The method has a very high detection rate of foetal malformations above 99%.

  1. Cordocentesis (Percutaneous Umbilical Cord Blood sampling – PUBS) – an invasive prenatal diagnostic test

It involves puncturing the umbilical vein with a needle (transplacental or transvaginal puncture) and collecting foetal blood for further examination. Cordocentesis is an invasive procedure with the risk of complications including: blood loss at the place of needle insertion, infection, decreased foetal heart rate, rupture of the amnion and spontaneous abortion (miscarriage). The method has a very high detection rate of foetal malformations above 99%.

Comparison of prenatal testing methods

MethodInvasive/
Non-invasive
When is it done (week of pregnancy)Detection rate of foetal defectsRisk/
complications
Medfemina offer
1. Nifty PRO testNon-invasive12 - 24 weeks (recommended 12-16 weeks)Detection rate above 99%, false-positive results around 1%No risk of miscarriageYES
2. FMF testNon-invasive11 - 13 week +6daysDetection rate 85% - 90%, false-positive results around 5%No risk of miscarriageYES
3. NT nuchal translucency measurementNon-invasive11 - 13 week +6daysDetection rate 64% - 70%No risk of miscarriageYES
4. Biochemical tests from maternal bloodNon-invasive11 - 13 week +6days

14 - 20 week +6days
Detection rate 60% - 80%

false-positive results around 5%
No risk of miscarriageYES
5. Chorionic villus sampling (CVS)Invasive10 - 14 weekDetection rate over 99%Risk of miscarriage (1% - 2%)

Risk of minor bleeding

Risk of amniotic fluid leakage
NO
6. AmniocentesisInvasive15 - 21 weekDetection rate over 99%Risk of miscarriage (0.5% - 1%)

Risk of placental damage, foetal organ puncture, intrauterine infection, rupture of the amnion.
YES
7. Cordocentesis (PUBS)Invasive12 - 24 weekRisk of miscarriage (1% - 2%)

Risk of blood loss at the site of needle insertion, infection, decreased foetal heart rate, rupture of the amnion
Risk of miscarriage (1% - 2%)

Risk of blood loss at the site of needle insertion, infection, decreased foetal heart rate, rupture of the amnion
NO
Call Now Button